Lakewood-Amedex updates S-1, adds detail on Nu-3 pipeline and Series C conversion mechanics

Lakewood-Amedex Biotherapeutics Inc. filed a Form S-1 on September 18, 2026, registering additional shares of common stock issuable upon conversion of Series C Preferred Stock held by a selling stockholder from a private placement that closed on April 21, 2026¹. The new registration covers 4,512,400 shares.

The Series C Preferred converts at a price subject to a $1.00 per share floor, and when the company's one-for-ten reverse stock split took effect on June 19, 2026, that floor was not adjusted, which increased the maximum shares issuable on conversion.¹ Since an earlier registration became effective, holders converted 322,061 Series C shares before the split and another 164,199 shares between June 22 and July 6, 2026, for a total of 486,260 shares converted into 937,500 shares of common stock.¹ The company says it is now obligated to register shares covering the remaining 451,240 Series C shares, worth $4,512,400 at stated value, which at the $1.00 floor could require up to 4,512,400 additional common shares.¹

On the clinical side, the filing details progress on lead candidate Nu-3, a topical Bisphosphocin antibacterial for infected diabetic foot ulcers. The company has completed early exploratory human trials and plans an initial Phase 2a safety and dose-response study followed by a placebo-controlled Phase 2b study to select a dose for Phase 3.¹ The Phase 2a study (NCT0765506) has IRB approvals completed and is open and enrolling, comprising 24 patients across 2%, 5%, and 10% Nu-3 gel doses.¹ The company plans to begin the open-label study immediately after the Series C financing and subsequent Nasdaq listing, with proceeds expected to fund completion of the Phase 2a study.¹

Lakewood-Amedex trades on Nasdaq under "LABT," and its last reported sale price on September 17, 2026 was $1.86 per share.¹ The company will not receive proceeds from the resale shares covered by the prospectus.¹